Schizophrenia

A new review article is suggesting a number of psychiatric disorders share common gut microbiome perturbations. The meta-analysis found depression, bipolar disorder, schizophrenia, and anxiety all present with similar gut microbial abnormalities.

Through experiments on mice with a genetic mutation that causes schizophrenia, scientists in Japan believe they have happened upon a new drug to tackle the disease, and one that is already approved for use as a dietary supplement.

A new study is presenting a robust hypothesis to explain how a parasitic infection can alter behavior. The research provides new insights into how neurophysiological changes influence behavior, and points to novel therapeutic research targets.

A pair of studies are showing how passive smartphone data can be used to predict relapse episodes in schizophrenia patients. The research used machine learning to analyze behavioral data and predict schizophrenic relapses up to one month before they occurred.

An international team of researchers has used machine learning to produce a novel blood test that can predict a young person’s risk of developing a psychotic disorder, such as schizophrenia, years before the condition develops.

Scientists investigating the driving factors behind certain neurological diseases have uncovered a new class of proteins that could help us intervene in some of the destructive processes that take place in the brain.

A new study investigating brain activity patterns in schizophrenia patients and their siblings is suggesting a specific brain “signature” could detect the condition in subjects before clinical symptoms appear.

A study has homed in on the sex-specific activity of a gene that both increases risk of developing schizophrenia and decreases the risk of developing lupus, offering novel insights into how some diseases appear in different rates in men and women.

Promising new research from the University of California, Los Angeles (UCLA), suggests an old schizophrenia drug could significantly enhance the efficacy of radiation treatment for one of the deadliest forms of brain cancer.

A new study is reporting the successful results of a clinical trial testing an experimental drug designed to treat psychosis in schizophrenia. The drug works unlike any other existing anti-psychotic medication and larger Phase 3 trials are underway.

New research has analyzed hundreds of brain scans from patients with schizophrenia revealing two distinct subtypes with differences in gray matter volumes, busting the previously held notion that all schizophrenia patients' brains are the same.

A team of researchers from King’s College London has, for the first time, imaged the brains of patients with psychosis under the influence of CBD. The study demonstrates the anti-psychotic potential of CBD, suggesting clinical trials are necessary.